Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Period	fcf
2016-12-31	-$24.27M
2017-12-31	-$57.26M
2018-12-31	-$22.57M
2019-12-31	-$71.58M
2020-12-31	-$52.12M
2021-12-31	-$70.17M
2022-12-31	-$35.87M
2023-12-31	-$85.94M
2024-12-31	-$65.03M
2025-12-31	-$39.64M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABUS	$4.60	-0.86%	1.03M
3
4
5

Arbutus Biopharma Corporation (ABUS) Free Cash Flow

Free Cash Flow Data

Get Arbutus Biopharma Corporation Data in Excel

More ABUS Financial Data